Tata Consultancy Services has been selected by QIAGEN, one of the leading global providers of Sample to Insights solutions in life sciences and molecular diagnostics, as the strategic partner for its cloud transformation journey.
QIAGEN is investing in cloud transformation to address new challenges of the post-pandemic era. It partnered with TCS for its deep contextual knowledge of the company’s infrastructure, applications, and systems, vast experience in the life sciences industry as well as proven technical expertise.
TCS will migrate the company’s workloads from its legacy data centre to Microsoft Azure and build a new scalable digital core as a foundation for better ways of working, the company said.
TCS’ team of cloud solution experts will work closely with QIAGEN to design, implement and manage a cloud-first model. The new digital core will help improve internal and external collaboration, enabling greater innovation, and enhanced customer experience.
Additionally, it will improve operational agility and resilience, drive efficiency, reduce QIAGEN’s carbon footprint and support its journey to net zero.
“QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth. A strong digital core will help QIAGEN to deliver innovation in a faster, more cost-efficient, and secure way. TCS has been a valuable strategic partner on this journey so far who will help us succeed in this cloud transformation,” said Josefine Danneberg, Senior Director, Head of Cloud Center of Excellence, QIAGEN.
“QIAGEN is a valued TCS customer, and we are thrilled to enter into this partnership to implement and manage their cloud strategy with Azure as the hyperscaler. The new digital core will support better business outcomes and greater sustainability and drive innovation for QIAGEN’s customers in life sciences and molecular diagnostics. We look forward to working alongside QIAGEN to support the company in achieving its vision of ‘making improvements in life possible,” said Vikas Jain, Global Head, Life Sciences and Healthcare, Enterprise Growth Group, TCS.